Treatment of Sézary Syndrome with Cyclosporin A

Puttick, Linda; Pollock, Andrew; Fairburn, E. A.

doi:10.1177/014107688307601216

Cited by 22 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sézary syndrome is thought to be the leukemic form of this cutaneous lymphoma with the malignant T cells spreading from the skin to the blood and lymph nodes. A few reports have claimed a beneficial effect o f ciclosporin A in cases of Sézary syndrome [3,4] while others, however, have noted progression of the disease following treatm ent with ciclosporin A [5].…”

Section: Introductionmentioning

confidence: 99%

Extracutaneous Spreading with Fatal Outcome of Mycosis fungoides in a Patient Treated with Ciclosporin A: A Word of Caution

Thomsen¹,

Wantzin

1987

Dermatology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Extracutaneous Spreading with Fatal Outcome of Mycosis fungoides in a Patient Treated with Ciclosporin A: A Word of Caution

Thomsen¹,

Wantzin

1987

Dermatology

View full text Add to dashboard Cite

show abstract

“…1982 & Adler. 1983) and clinical therapy of T-cell disease has been attempted (Puttick et al. 1983: Morland et al.…”

mentioning

confidence: 99%

Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro

Twentyman

Wright²,

Wallace³

1992

Br J Cancer

View full text Add to dashboard Cite

We have studied the ability of cyclosporin A (CsA) and a non-immunosuppressive analogue, O-acetyl cyclosporin A (OACsA, B3-243) to inhibit the growth of human lung cancer cells in vitro. Using continuous drug exposure and the MTT colorimetric assay to determine cell growth we found that CsA produced partial growth inhibition at doses ranging from 0.5 to 3.0 micrograms ml-1 (0.4-2.4 microM). At progressively higher doses, complete growth inhibition and in situ cell lysis were seen. The P-glycoprotein expressing multidrug resistant (MDR) variant H69/LX4 of the small cell line H69/P was less sensitive to cyclosporins than the parent line, but this was not true of the non-P-glycoprotein expressing MDR variants of large cell line COR-L23 or adenocarcinoma line MOR. Sensitivity to OACsA was approximately 2-fold higher than that to CsA in most of the lines although not in the most sensitive line, COR-L88. Even in COR-L88, exposed to CsA or OACsA for 24 h, clonogenic cell survival was reduced only to 50%. There was no reduction in polyamine content of COR-L23 or COR-L88 cells following 48 h of exposure to CsA or OACsA. The effects on cell growth could not be inhibited by the addition of exogenous putrescine, nor could they be enhanced by the addition of alpha-difluoromethylorthinine. It does not appear therefore that inhibition of polyamine synthesis is the basis of the observed growth inhibition.

show abstract

Dermatologic Applications of Cyclosporine

Biren¹

1986

Arch Dermatol

View full text Add to dashboard Cite

It is evident that cyclosporine A is a potent immunosuppressive agent and may become immensely valuable in the treatment of cutaneous disease. The extent of its application and efficacy is speculative, as neither the pathogenesis of many of the diseases, nor the mechanism of action of cyclosporine is fully understood. Well-designed clinical and laboratory studies are necessary to delineate its therapeutic value in a particular disorder. It must be emphasized that the systemic use of the drug is associated with several serious side effects, including nephrotoxicity and lymphoproliferative disease. Local topical application may reduce these concerns, and make treatment of benign diseases a possibility. Therefore, until these well-designed prospective studies are performed, cyclosporine's use should be limited and closely monitored.

show abstract

Treatment of Sézary Syndrome with Cyclosporin A

Cited by 22 publications

References 12 publications

Extracutaneous Spreading with Fatal Outcome of Mycosis fungoides in a Patient Treated with Ciclosporin A: A Word of Caution

Extracutaneous Spreading with Fatal Outcome of Mycosis fungoides in a Patient Treated with Ciclosporin A: A Word of Caution

Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro

Dermatologic Applications of Cyclosporine

Contact Info

Product

Resources

About